Kymera Therapeutics (KYMR) Enterprise Value (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Enterprise Value data on file, last reported at -$650.9 million in Q1 2026.

• Enterprise Value for Q1 2026 came in at -$650.9 million, down 40.54% year-over-year; the trailing twelve-month figure through Mar 2026 was -$650.9 million (down 40.54% YoY), and the FY2025 annual result was -$848.3 million, down 73.56% from the prior year.
• Enterprise Value climbed to -$650.9 million in Q1 2026 per KYMR's latest filing, from -$848.3 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$33.7 million in Q1 2022 and troughed at -$848.3 million in Q4 2025.
• A 5-year average of -$452.9 million and a median of -$481.9 million in 2022 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2023: Enterprise Value jumped 89.89% in 2022, then plunged 1076.52% in 2023.
• A 5-year view of Enterprise Value shows it stood at -$407.2 million in 2022, then gained by 7.93% to -$374.9 million in 2023, then sank by 30.37% to -$488.7 million in 2024, then tumbled by 73.56% to -$848.3 million in 2025, then grew by 23.26% to -$650.9 million in 2026.
• Business Quant data shows KYMR's Enterprise Value at -$650.9 million in Q1 2026, -$848.3 million in Q4 2025, and -$505.7 million in Q3 2025.